Form 4: Vaxcyte COO Jim Wassil Reports Stock Option Exercise and Common Stock Acquisition
SEC Form 4 Filing
Vaxcyte's Chief Operating Officer, Jim Wassil, exercised stock options and acquired 3,551 shares of common stock on April 17, 2024.
Summary
- On April 17, 2024, Jim Wassil, the Chief Operating Officer of Vaxcyte, Inc. (PCVX), exercised stock options to acquire 3,551 shares of common stock at a price of $5.35 per share.
- Following this transaction, Wassil directly owns 221,840 shares of Vaxcyte common stock.
- Wassil also holds 78,611 derivative securities in the form of stock options.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of an insider transaction. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the actions of company executives. It's a standard practice for publicly traded companies and their officers.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, as it's a routine insider transaction.
Key Dates
| Date | Description |
|---|---|
| 04/17/2024 | Date of stock option exercise and common stock acquisition |
| 04/17/2030 | Expiration date of the stock options |
| 04/19/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.